Home / Health / Himachal Drug Samples Fail Quality Tests: 50 Sub-Standard, 7 Spurious
Himachal Drug Samples Fail Quality Tests: 50 Sub-Standard, 7 Spurious
23 Jan
Summary
- Fifty drug samples from Himachal failed quality tests conducted by CDSCO.
- Seven drug samples were declared spurious, indicating potential counterfeiting.
- The affected drugs included various treatments for common ailments and conditions.
In a significant development, the Central Drugs Standard Control Organisation (CDSCO) has identified 50 sub-standard drug samples originating from Himachal Pradesh. Even more concerning, seven of these samples were classified as spurious, suggesting a serious threat to public health.
These failed samples, tested in December 2025, were collected from various manufacturing hubs, with a substantial number originating from the Baddi industrial area. The affected medications span a range of critical treatments, including those for bacterial infections, asthma, high blood pressure, and kidney problems.
This revelation comes at a time when Himachal Pradesh contributes significantly to India's pharmaceutical output, representing approximately 35% of the nation's total drug production annually. In November 2025, a prior CDSCO report also highlighted issues, with 49 drug samples from the state failing quality tests.
